Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
10
6
2022
medline:
27
8
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
After a 1-y absence due to the coronavirus disease 2019 pandemic, the 26th Annual Congress of the International Liver Transplantation Society was held from May 15 to 18, 2021, in a virtual format. Clinicians and researchers from all over the world came together to share their knowledge on all the aspects of liver transplantation (LT). Apart from a focus on LT in times of coronavirus disease 2019, featured topics of this year's conference included infectious diseases in LT, living donation, machine perfusion, oncology, predictive scoring systems and updates in anesthesia/critical care, immunology, radiology, pathology, and pediatrics. This report presents highlights from invited lectures and a review of the select abstracts. The aim of this report, generated by the Vanguard Committee of International Liver Transplantation Society, is to provide a summary of the most recent developments in clinical practice and research in LT.
Identifiants
pubmed: 35676871
doi: 10.1097/TP.0000000000004183
pii: 00007890-202209000-00015
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1738-1744Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
International Liver Transplantation Society. Abstract Book of the ILTS 2021 Conference [Internet]. 2021. Available at: https://www.professionalabstracts.com/ilts2021/iplanner/#/grid . Accessed January 06, 2021.
Aubert O, Yoo D, Zielinski D, et al. COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health. 2021;6:e709–e719.
Idalsoaga F, Ayares G, Arab JP, et al. COVID-19 and indirect liver injury: a narrative synthesis of the evidence. J Clin Transl Hepatol. 2021;9:760–768.
Roche B, Roque-Afonso AM, Nevens F, et al. Rational basis for optimizing short and long-term hepatitis B virus prophylaxis post liver transplantation: role of hepatitis B immune globulin. Transplantation. 2015;99:1321–1334.
Terrault N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Am J Gastroenterol. 2013;108:949–951.
Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67:585–602.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.
Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587–593.
Lenci I, Baiocchi L, Tariciotti L, et al. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression. Liver Transpl. 2016;22:1205–1213.
Orfanidou A, Papatheodoridis GV, Cholongitas E. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: current concepts. Liver Int. 2021;41:1448–1461.
Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272–279.
Doyle A, Adeyi O, Khalili K, et al. Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation. Liver Transpl. 2016;22:1295–1300.
Nakamuta M, Morizono S, Soejima Y, et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation. 2005;80:608–612.
Rose JT, Vargas P, Seay T, et al. Lose weight to donate: development of a program to optimize potential donors with hepatic steatosis or obesity for living liver donation. Transplant Direct. 2021;7:e702.
Kalisvaart M, Croome KP, Hernandez-Alejandro R, et al. Donor warm ischemia time in DCD liver transplantation-working group report from the ILTS DCD, Liver Preservation, and Machine Perfusion Consensus Conference. Transplantation. 2021;105:1156–1164.
Schlegel A, Foley DP, Savier E, et al. Recommendations for donor and recipient selection and risk prediction: working group report from the ILTS Consensus Conference in DCD Liver Transplantation. Transplantation. 2021;105:1892–1903.
Quintini C, Muiesan P, Detry O, et al. Early allograft dysfunction and complications in DCD liver transplantation: expert consensus statements from the International Liver Transplantation Society. Transplantation. 2021;105:1643–1652.
Hessheimer AJ, Polak W, Antoine C, et al. Regulations and procurement surgery in DCD liver transplantation: expert consensus guidance from the International Liver Transplantation Society. Transplantation. 2021;105:945–951.
Schlegel A, van Reeven M, Croome K, et al.; DCD Collaborator Group. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation. J Hepatol. 2022;76:371–382.
Nasralla D, Coussios CC, Mergental H, et al.; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557:50–56.
Mergental H, Laing RW, Kirkham AJ, et al. Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat Commun. 2020;11:2939.
van Rijn R, Schurink IJ, de Vries Y, et al.; DHOPE-DCD Trial Investigators. Hypothermic machine perfusion in liver transplantation - a randomized trial. N Engl J Med. 2021;384:1391–1401.
Martins PN, Rizzari MD, Ghinolfi D, et al.; ILTS Special Interest Group “DCD, Preservation and Machine Perfusion”. Design, analysis, and pitfalls of clinical trials using ex situ liver machine perfusion: the international liver transplantation society consensus guidelines. Transplantation. 2021;105:796–815.
Guo Z, Zhao Q, Huang S, et al. Ischaemia-free liver transplantation in humans: a first-in-human trial. Lancet Reg Health West Pac. 2021;16:100260.
Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct. 2018;4:e376.
Londoño MC, Reig M; RETOINMUNO Multidisciplinary Group. Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors. Cancers (Basel). 2020;12:E3446.
De Martin E, Michot JM, Rosmorduc O, et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2:100170.
Feng S, Bucuvalas JC, Mazariegos GV, et al. Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving toward personalized management. Hepatology. 2021;73:1985–2004.
de Barros F, Cardoso Faleiro Uba PH. Liver transplantation and bariatric surgery: a new surgical reality: a systematic review of the best time for bariatric surgery. Updates Surg. 2021;73:1615–1622.
Bhanji RA, Takahashi N, Moynagh MR, et al. The evolution and impact of sarcopenia pre- and post-liver transplantation. Aliment Pharmacol Ther. 2019;49:807–813.
Smith NK, Zerillo J, Kim SJ, et al. Intraoperative cardiac arrest during adult liver transplantation: incidence and risk factor analysis from 7 academic centers in the United States. Anesth Analg. 2021;132:130–139.
Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet. 2008;372:554–561.
Izzy M, VanWagner LB, Lin G, et al.; Cirrhotic cardiomyopathy Consortium. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020;71:334–345.
Reddy MS, Rajalingam R, Rela M. Revisiting APOLT for metabolic liver disease: a new look at an old idea. Transplantation. 2017;101:260–266.